ZA200201407B - Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction. - Google Patents

Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction. Download PDF

Info

Publication number: ZA200201407B
Authority: ZA; South Africa
Prior art keywords: substance; composition; dapoxetine; administration; sexual
Prior art date: 1999-09-03

Application number

ZA200201407A

Other languages

English (en)

Inventor

Karl Bruce Thor

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-03

Filing date

2002-02-19

Publication date

2003-07-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200201407(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-07-30 Publication of ZA200201407B publication Critical patent/ZA200201407B/en

Links

238000000034 method Methods 0.000 title claims description 71
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title claims description 59
239000012896 selective serotonin reuptake inhibitor Substances 0.000 title claims description 59
201000001880 Sexual dysfunction Diseases 0.000 title claims description 39
231100000872 sexual dysfunction Toxicity 0.000 title claims description 39
USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical group C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 118
229960005217 dapoxetine Drugs 0.000 claims description 116
239000000203 mixture Substances 0.000 claims description 89
239000003814 drug Substances 0.000 claims description 85
238000011282 treatment Methods 0.000 claims description 80
230000001568 sexual effect Effects 0.000 claims description 67
150000003839 salts Chemical class 0.000 claims description 64
206010036596 premature ejaculation Diseases 0.000 claims description 52
239000000126 substance Substances 0.000 claims description 48
241000124008 Mammalia Species 0.000 claims description 21
239000002552 dosage form Substances 0.000 claims description 20
238000009472 formulation Methods 0.000 claims description 16
239000008177 pharmaceutical agent Substances 0.000 claims description 12
229940124597 therapeutic agent Drugs 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
239000005022 packaging material Substances 0.000 claims description 9
206010063659 Aversion Diseases 0.000 claims description 4
230000035946 sexual desire Effects 0.000 claims description 4
229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 2
239000008184 oral solid dosage form Substances 0.000 claims 2
239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 55
229940079593 drug Drugs 0.000 description 50
239000000902 placebo Substances 0.000 description 50
229940068196 placebo Drugs 0.000 description 50
239000003826 tablet Substances 0.000 description 34
238000002560 therapeutic procedure Methods 0.000 description 30
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
239000004480 active ingredient Substances 0.000 description 23
239000002775 capsule Substances 0.000 description 19
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 18
229960002296 paroxetine Drugs 0.000 description 18
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 17
230000000694 effects Effects 0.000 description 15
239000000546 pharmaceutical excipient Substances 0.000 description 15
238000007726 management method Methods 0.000 description 13
230000001965 increasing effect Effects 0.000 description 12
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 11
-1 alprostadil Chemical class 0.000 description 11
230000001684 chronic effect Effects 0.000 description 11
238000013270 controlled release Methods 0.000 description 11
229960002464 fluoxetine Drugs 0.000 description 11
229940076279 serotonin Drugs 0.000 description 11
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
229960002073 sertraline Drugs 0.000 description 10
230000003466 anti-cipated effect Effects 0.000 description 9
230000008901 benefit Effects 0.000 description 9
230000002265 prevention Effects 0.000 description 9
238000002483 medication Methods 0.000 description 8
229920002472 Starch Polymers 0.000 description 7
230000008859 change Effects 0.000 description 7
238000007906 compression Methods 0.000 description 7
230000006835 compression Effects 0.000 description 7
239000008187 granular material Substances 0.000 description 7
230000006872 improvement Effects 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000013543 active substance Substances 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
201000001881 impotence Diseases 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
210000003899 penis Anatomy 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000008107 starch Substances 0.000 description 6
USRHYDPUVLEVMC-HXUWFJFHSA-N (1r)-n,n-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine Chemical compound C1([C@@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-HXUWFJFHSA-N 0.000 description 5
208000010228 Erectile Dysfunction Diseases 0.000 description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
238000012216 screening Methods 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
235000019759 Maize starch Nutrition 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
230000002411 adverse Effects 0.000 description 4
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
230000035515 penetration Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
229960000836 amitriptyline Drugs 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000037452 priming Effects 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
230000000697 serotonin reuptake Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000237858 Gastropoda Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
230000037007 arousal Effects 0.000 description 2
238000013542 behavioral therapy Methods 0.000 description 2
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
239000007894 caplet Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960004782 chlordiazepoxide Drugs 0.000 description 2
210000003029 clitoris Anatomy 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000009429 distress Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000001856 erectile effect Effects 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229960004038 fluvoxamine Drugs 0.000 description 2
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
230000037406 food intake Effects 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000007897 gelcap Substances 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000002547 new drug Substances 0.000 description 2
QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
230000011514 reflex Effects 0.000 description 2
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
230000002295 serotoninergic effect Effects 0.000 description 2
DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229960004688 venlafaxine Drugs 0.000 description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
229960000317 yohimbine Drugs 0.000 description 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 description 1
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
LLJKLSASLJIYAO-UHFFFAOYSA-N 3-naphthalen-1-yloxy-1-phenylpropan-1-amine Chemical class C=1C=CC2=CC=CC=C2C=1OCCC(N)C1=CC=CC=C1 LLJKLSASLJIYAO-UHFFFAOYSA-N 0.000 description 1
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010057672 Male sexual dysfunction Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
241001602876 Nata Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229960000711 alprostadil Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
229960002980 amitriptyline oxide Drugs 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940125713 antianxiety drug Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000000330 cholinergic fiber Anatomy 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
229960004606 clomipramine Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
210000005226 corpus cavernosum Anatomy 0.000 description 1
229940072645 coumadin Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
229940008099 dimethicone Drugs 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
229960003602 guanethidine Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000009532 heart rate measurement Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
230000000423 heterosexual effect Effects 0.000 description 1
KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
239000000938 histamine H1 antagonist Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
229960002672 isocarboxazid Drugs 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960003955 mianserin Drugs 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
229960001785 mirtazapine Drugs 0.000 description 1
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
USRHYDPUVLEVMC-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OCCC(N(C)C)C1=CC=CC=C1 USRHYDPUVLEVMC-UHFFFAOYSA-N 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
210000002640 perineum Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229960000964 phenelzine Drugs 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
230000036515 potency Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
229960005253 procyclidine Drugs 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
229940124811 psychiatric drug Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229960002639 sildenafil citrate Drugs 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000016166 striated muscle contraction Effects 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
229940098466 sublingual tablet Drugs 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229960003741 tranylcypromine Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
206010046947 vaginismus Diseases 0.000 description 1
229940072690 valium Drugs 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000006441 vascular event Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229940094720 viagra Drugs 0.000 description 1
238000009528 vital sign measurement Methods 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
229940071104 xylenesulfonate Drugs 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200201407A 1999-09-03 2002-02-19 Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction. ZA200201407B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15243599P	1999-09-03	1999-09-03

Publications (1)

Publication Number	Publication Date
ZA200201407B true ZA200201407B (en)	2003-07-30

Family

ID=22542905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201407A ZA200201407B (en)	1999-09-03	2002-02-19	Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction.

Country Status (34)

Country	Link
US (4)	US7718705B1 (xx)
EP (3)	EP1671628B1 (xx)
JP (1)	JP3194734B2 (xx)
KR (1)	KR100719977B1 (xx)
CN (1)	CN1222283C (xx)
AT (1)	ATE318135T1 (xx)
AU (1)	AU762934B2 (xx)
BE (1)	BE2012C040I2 (xx)
BG (1)	BG65677B1 (xx)
BR (1)	BR0014166A (xx)
CA (1)	CA2383785C (xx)
CY (1)	CY2012028I2 (xx)
CZ (1)	CZ299712B6 (xx)
DE (2)	DE122009000036I2 (xx)
DK (1)	DK1225881T3 (xx)
EA (1)	EA004101B1 (xx)
EE (1)	EE05315B1 (xx)
ES (2)	ES2393582T3 (xx)
FR (1)	FR12C0052I2 (xx)
HK (2)	HK1047545B (xx)
HR (1)	HRP20020189A2 (xx)
HU (1)	HU229150B1 (xx)
IL (2)	IL148159A0 (xx)
LU (1)	LU92204I2 (xx)
MX (1)	MXPA02001811A (xx)
MY (1)	MY125490A (xx)
NO (2)	NO330562B1 (xx)
NZ (1)	NZ517038A (xx)
PL (1)	PL211402B1 (xx)
SI (1)	SI1225881T1 (xx)
TW (3)	TW200524582A (xx)
UA (1)	UA75580C2 (xx)
WO (1)	WO2001017521A1 (xx)
ZA (1)	ZA200201407B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6403597B1 (en)	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DE122009000036I2 (de) *	1999-09-03	2010-05-06	Apbi Holdings Llc	Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion
ATE326957T1 (de)	2001-03-16	2006-06-15	Dmi Biosciences Inc	Verwendung von tramadol zur verzögerung der ejakulation
MXPA03008807A (es)	2001-03-29	2004-02-12	Bristol Myers Squibb Co	Derivados de ciclopropilindol como inhibidores selectivos de recaptacion de serotonina.
CA2410966C (en) *	2002-11-01	2005-11-22	Craig J. Hudson	Sexual desire and performance enhancement with protein-bound tryptophan
AU2003903597A0 (en) *	2003-07-11	2003-07-24	Jakov Vaisman	Treatment of premature ejaculation
GB0318706D0 (en) *	2003-08-08	2003-09-10	Pfizer Ltd	Selective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (de)	2009-03-31	2010-10-07	Ratiopharm Gmbh	Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
DE102009058321A1 (de)	2009-12-15	2011-06-16	Ratiopharm Gmbh	Schmelztablette, enthaltend Dapoxetin
WO2012005500A2 (ko)	2010-07-06	2012-01-12	주식회사 네비팜	다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
RU2463033C2 (ru) *	2010-08-06	2012-10-10	Василий Федорович Пятин	Способ лечения преждевременной эякуляции
CN103100085A (zh) *	2011-11-09	2013-05-15	上海兰蒂斯生物医药科技有限公司	一种药物组合物
CN103130660B (zh) *	2011-11-25	2014-09-17	厦门福满药业有限公司	一类达泊西汀的酸式盐及其晶体,以及晶体的制备方法
WO2014042416A1 (ko) *	2012-09-13	2014-03-20	주식회사 씨티씨바이오	다폭세틴 유리염기를 함유하는 경구용 조성물
KR101432905B1 (ko)	2012-12-11	2014-08-21	가톨릭대학교 산학협력단	다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물
US20160101093A1 (en) *	2013-05-21	2016-04-14	Jason B. Wynberg	Methods for the treatment of premature ejaculation
CN103735525B (zh) *	2014-02-12	2015-05-06	江苏仁寿药业有限公司	一种达泊西汀片剂及制备方法
WO2016025541A1 (en) *	2014-08-12	2016-02-18	Tianxin Wang	Therapeutical methods, formulations and nutraceutical formulations
US20180071269A1 (en)	2015-08-12	2018-03-15	Tianxin Wang	Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) *	2016-11-30	2018-06-07	Wang tian xin	Therapeutical methods, formulations and nutraceutical formulations
TR201620151A2 (en)	2016-12-30	2018-07-23	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113181127A (zh) *	2021-05-07	2021-07-30	苏州康恒研新药物技术有限公司	一种盐酸达泊西汀微丸片的制备方法
CN113143879A (zh) *	2021-05-07	2021-07-23	苏州康恒研新药物技术有限公司	一种盐酸达泊西汀缓释片的制备方法
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4018895A (en) *	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
US4194009A (en) *	1974-01-10	1980-03-18	Eli Lilly And Company	Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en) *	1978-06-22	1980-06-10	Eli Lilly And Company	1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en) *	1980-10-31	1982-05-11	Eli Lilly And Company	Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5135947A (en) *	1987-04-09	1992-08-04	Eli Lilly And Company	1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en)	1988-05-31	1989-09-12	Top Laboratories, Inc.	Low-dosage sublingual aspirin
US5082667A (en)	1988-06-07	1992-01-21	Abbott Laboratories	Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en)	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US4940731A (en)	1989-08-30	1990-07-10	Pfizer Inc.	Method of treating premature ejaculation using sertraline
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5589511A (en)	1990-08-13	1996-12-31	Sepracor Inc.	Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en)	1991-07-12	1992-09-29	Crenshaw Roger T	Method for treating premature ejaculation
US5151488A (en) *	1991-11-12	1992-09-29	The Mead Corporation	Liquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en)	1992-08-13	1993-09-28	Pfizer Inc.	Sertraline polymorph
US5292962A (en)	1992-12-11	1994-03-08	Eli Lilly And Company	Intermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en) *	1993-02-01	1993-06-03	Lilly Co Eli	Pharmaceutical treatments.
US5276042A (en)	1993-04-16	1994-01-04	Crenshaw Roger T	Treatment of premature ejaculation
IT1264965B1 (it)	1993-11-12	1996-10-17	Giorgio Cavallini	Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ATE189121T1 (de)	1994-04-22	2000-02-15	Pentech Pharmaceuticals Inc	Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
CA2134038C (en)	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5457121A (en)	1994-09-02	1995-10-10	Eli Lilly And Company	Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en) *	1994-09-14	1997-01-28	Pfizer Inc.	Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en)	1994-10-20	1997-04-16	Lilly Co Eli	Treatment of disorders with duloxetine
EP0714663A3 (en) *	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
US5789402A (en)	1995-01-17	1998-08-04	Eli Lilly Company	Compounds having effects on serotonin-related systems
US5627196A (en)	1995-01-17	1997-05-06	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5576321A (en)	1995-01-17	1996-11-19	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5614523A (en)	1995-01-17	1997-03-25	Eli Lilly And Company	Compounds having effects on serotonin-related systems
AU4918796A (en)	1995-02-10	1996-08-27	Eli Lilly And Company	Methods of treating or preventing psychiatric disorders
US5624677A (en)	1995-06-13	1997-04-29	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
NZ320216A (en)	1995-10-13	1999-05-28	Neurosearch As	8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use
US5758911A (en) *	1996-02-07	1998-06-02	Northrop Grumman Corporation	Linear motion wind driven power plant
US5897864A (en)	1996-05-23	1999-04-27	Cohen; Alan J.	Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en)	1996-06-14	1998-12-08	Eli Lilly And Company	Inhibition of serotonin reuptake
US5912256A (en)	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5830500A (en) *	1996-07-22	1998-11-03	Pentech Pharmaceuticals, Inc.	Low dose fluoxetine tablet
US6638948B1 (en)	1996-09-09	2003-10-28	Pentech Pharmaceuticals, Inc.	Amorphous paroxetine composition
US5672612A (en)	1996-09-09	1997-09-30	Pentech Pharmaceuticals, Inc.	Amorphous paroxetine composition
US5910319A (en)	1997-05-29	1999-06-08	Eli Lilly And Company	Fluoxetine enteric pellets and methods for their preparation and use
CN1475209A (zh)	1997-07-01	2004-02-18	�Ʒ�	舍曲林的缓释剂型
AU739261B2 (en)	1997-07-01	2001-10-11	Pfizer Inc.	Sertraline salts and sustained-release dosage forms of sertraline
EA001905B1 (ru)	1997-07-01	2001-10-22	Пфайзер Продактс Инк.	Лекарственная форма сертралина в виде раствора, заключенного в желатиновые капсулы
FR2765483B1 (fr) *	1997-07-04	2000-02-04	Philippe Gorny	Medicament destine a traiter les dysfonctions erectiles
US6037360A (en)	1997-10-28	2000-03-14	Vivus, Incorporated	Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en)	1997-10-28	1999-07-13	Vivus, Incorporated	Local administration of pharmacologically active agents to treat premature ejaculation
US6228864B1 (en)	1997-10-28	2001-05-08	Vivus, Inc.	Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
UA66370C2 (en)	1997-12-16	2004-05-17	Lilly Co Eli	Arylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (es)	1998-04-09	2000-09-29	Pfizer Prod Inc	Ligandos azabiciclicos de receptores 5ht1
WO1999065492A1 (en)	1998-06-19	1999-12-23	Eli Lilly And Company	Inhibition of serotonin reuptake
US6303627B1 (en)	1998-06-19	2001-10-16	Eli Lilly And Company	Inhibitors of serotonin reuptake
FR2781671A1 (fr)	1998-07-28	2000-02-04	Synthelabo	Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6150376A (en)	1998-08-05	2000-11-21	Georgetown University	Bi- and tri-cyclic aza compounds and their uses
UA72743C2 (en)	1998-10-13	2005-04-15	Pfizer Prod Inc	Essentially nonaqueous liquid pharmaceutical concentrate composition containing sertraline, method of using this concentrate, method for treatment
AU4982300A (en) *	1999-05-06	2000-11-21	Pentech Pharmaceuticals, Inc.	Regimen and kit for amelioration of premature ejaculation
US20010003120A1 (en) *	1999-05-14	2001-06-07	M. D. Robert Hines	Method for treating erectile dysfunction
DE122009000036I2 (de) *	1999-09-03	2010-05-06	Apbi Holdings Llc	Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion

2000
- 2000-08-22 DE DE122009000036C patent/DE122009000036I2/de active Active
- 2000-08-22 BR BR0014166-6A patent/BR0014166A/pt not_active Application Discontinuation
- 2000-08-22 ES ES06002333T patent/ES2393582T3/es not_active Expired - Lifetime
- 2000-08-22 CN CNB008153132A patent/CN1222283C/zh not_active Ceased
- 2000-08-22 UA UA2002031755A patent/UA75580C2/uk unknown
- 2000-08-22 PL PL364924A patent/PL211402B1/pl unknown
- 2000-08-22 DE DE60026146T patent/DE60026146T2/de not_active Expired - Lifetime
- 2000-08-22 EA EA200200324A patent/EA004101B1/ru not_active IP Right Cessation
- 2000-08-22 ES ES00957264T patent/ES2256032T3/es not_active Expired - Lifetime
- 2000-08-22 AT AT00957264T patent/ATE318135T1/de active
- 2000-08-22 CZ CZ20020784A patent/CZ299712B6/cs not_active IP Right Cessation
- 2000-08-22 HU HU0202687A patent/HU229150B1/hu active Protection Beyond IP Right Term
- 2000-08-22 SI SI200030828T patent/SI1225881T1/sl unknown
- 2000-08-22 EP EP06002333A patent/EP1671628B1/en not_active Expired - Lifetime
- 2000-08-22 NZ NZ517038A patent/NZ517038A/xx not_active IP Right Cessation
- 2000-08-22 WO PCT/US2000/020788 patent/WO2001017521A1/en active IP Right Grant
- 2000-08-22 MX MXPA02001811A patent/MXPA02001811A/es active IP Right Grant
- 2000-08-22 KR KR1020027002870A patent/KR100719977B1/ko active IP Right Review Request
- 2000-08-22 DK DK00957264T patent/DK1225881T3/da active
- 2000-08-22 EP EP07023209A patent/EP1889614A3/en not_active Withdrawn
- 2000-08-22 EE EEP200200107A patent/EE05315B1/xx active Protection Beyond IP Right Term
- 2000-08-22 CA CA002383785A patent/CA2383785C/en not_active Expired - Lifetime
- 2000-08-22 BG BG106461A patent/BG65677B1/bg unknown
- 2000-08-22 EP EP00957264A patent/EP1225881B1/en not_active Expired - Lifetime
- 2000-08-22 IL IL14815900A patent/IL148159A0/xx unknown
- 2000-08-22 US US10/049,427 patent/US7718705B1/en not_active Expired - Lifetime
- 2000-08-22 AU AU68911/00A patent/AU762934B2/en not_active Expired
- 2000-08-25 TW TW094107594A patent/TW200524582A/zh unknown
- 2000-08-25 TW TW098145182A patent/TWI367751B/zh not_active IP Right Cessation
- 2000-08-25 TW TW089117155A patent/TWI312678B/zh not_active IP Right Cessation
- 2000-08-29 JP JP2000259000A patent/JP3194734B2/ja not_active Expired - Lifetime
- 2000-08-29 MY MYPI20003983A patent/MY125490A/en unknown
2002
- 2002-02-14 IL IL148159A patent/IL148159A/en active IP Right Grant
- 2002-02-19 ZA ZA200201407A patent/ZA200201407B/en unknown
- 2002-02-28 HR HR20020189A patent/HRP20020189A2/hr not_active Application Discontinuation
- 2002-03-01 NO NO20021035A patent/NO330562B1/no not_active IP Right Cessation
- 2002-12-16 HK HK02109124.8A patent/HK1047545B/zh unknown
2004
- 2004-11-24 US US10/996,757 patent/US20050215617A1/en not_active Abandoned
- 2004-11-24 US US10/996,587 patent/US20050261377A1/en not_active Abandoned
2006
- 2006-11-30 HK HK06113173.6A patent/HK1091418A1/xx unknown
2012
- 2012-08-29 FR FR12C0052C patent/FR12C0052I2/fr active Active
- 2012-09-11 NO NO2012015C patent/NO2012015I2/no unknown
- 2012-10-11 BE BE2012C040C patent/BE2012C040I2/fr unknown
- 2012-10-23 CY CY2012028C patent/CY2012028I2/el unknown
2013
- 2013-05-23 LU LU92204C patent/LU92204I2/fr unknown
2014
- 2014-04-10 US US14/250,198 patent/US20140221497A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1047545B (zh)	2006-09-22
CZ2002784A3 (cs)	2002-09-11
DK1225881T3 (da)	2006-06-12
CZ299712B6 (cs)	2008-10-29
DE60026146D1 (de)	2006-04-27
NO2012015I2 (no)	2013-08-26
NO2012015I1 (no)	2012-09-11
HRP20020189A2 (en)	2004-02-29
HU229150B1 (hu)	2013-09-30
PL211402B1 (pl)	2012-05-31
EA200200324A1 (ru)	2002-08-29
CN1387432A (zh)	2002-12-25
BG65677B1 (bg)	2009-06-30
US20140221497A1 (en)	2014-08-07
IL148159A (en)	2009-11-18
NO330562B1 (no)	2011-05-16
IL148159A0 (en)	2002-09-12
LU92204I2 (fr)	2013-07-23
JP2001089394A (ja)	2001-04-03
EP1671628B1 (en)	2012-10-03
PL364924A1 (en)	2004-12-27
BG106461A (en)	2002-12-29
TWI367751B (en)	2012-07-11
TWI312678B (en)	2009-08-01
AU762934B2 (en)	2003-07-10
FR12C0052I1 (xx)	2012-05-10
SI1225881T1 (sl)	2006-06-30
CN1222283C (zh)	2005-10-12
AU6891100A (en)	2001-04-10
CA2383785C (en)	2009-02-17
ES2393582T3 (es)	2012-12-26
ES2256032T3 (es)	2006-07-16
EP1889614A2 (en)	2008-02-20
DE122009000036I2 (de)	2010-05-06
EP1225881B1 (en)	2006-02-22
DE60026146T2 (de)	2006-08-17
CY2012028I1 (el)	2017-04-05
HUP0202687A3 (en)	2006-03-28
BE2012C040I2 (xx)	2019-10-16
TW201018459A (en)	2010-05-16
KR100719977B1 (ko)	2007-05-21
BR0014166A (pt)	2002-05-14
EP1889614A3 (en)	2010-09-22
EE200200107A (et)	2003-04-15
FR12C0052I2 (fr)	2013-08-16
NO20021035L (no)	2002-05-02
NZ517038A (en)	2003-04-29
US20050261377A1 (en)	2005-11-24
KR20020025252A (ko)	2002-04-03
DE122009000036I1 (de)	2009-11-05
HK1091418A1 (en)	2007-01-19
WO2001017521A1 (en)	2001-03-15
US7718705B1 (en)	2010-05-18
EE05315B1 (et)	2010-08-16
JP3194734B2 (ja)	2001-08-06
NO20021035D0 (no)	2002-03-01
CY2012028I2 (el)	2017-04-05
EP1671628A1 (en)	2006-06-21
HUP0202687A2 (hu)	2002-12-28
UA75580C2 (uk)	2006-05-15
EA004101B1 (ru)	2003-12-25
HK1047545A1 (en)	2003-02-28
TW200524582A (en)	2005-08-01
US20050215617A1 (en)	2005-09-29
MY125490A (en)	2006-08-30
ATE318135T1 (de)	2006-03-15
MXPA02001811A (es)	2002-08-06
EP1225881A1 (en)	2002-07-31
CA2383785A1 (en)	2001-03-15

Publication	Publication Date	Title
US20140221497A1 (en)	2014-08-07	Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
CZ20013344A3 (cs)	2002-08-14	Farmaceutický prostředek vhodný pro léčení erektilní dysfunkce
CZ294350B6 (cs)	2004-12-15	Léčivo pro úpravu modulace krevního průtoku do genitálií a pro léčení impotence
EP1397126B1 (en)	2006-05-24	Use of tramadol for delaying ejaculation
WO2017201071A1 (en)	2017-11-23	Combination therapy for male sexual dysfunction
CZ20002939A3 (cs)	2000-12-13	Farmaceutické kombinace obsahující tramadol
KR20030077538A (ko)	2003-10-01	항우울제-유도된 성기능 장애를 아포모르핀을 사용하여치료하는 방법
JP2008519810A (ja)	2008-06-12	顔面紅潮の治療のためのｓミルタザピン
KR20210031922A (ko)	2021-03-23	간 질환의 가려움 증상 치료